Table 1 Baseline characteristics of eligible randomised patients
Bicalutamide (n = 79) Median (range)/n (%) | Bicalutamide + dutasteride (n = 71) Median (range)/n (%) | P | |
|---|---|---|---|
Age, years | 71 (54.2–86.1) | 73 (54.9–90.7) | 0.307† |
Baseline PSA (ng/mL) | 43.4 (11.6–15,000) | 46.3 (11.3–660) | 0.397† |
Clinical stage | 0.561* | ||
T1 | 2 (2.5) | 5 (7.0) | |
T2 | 12 (15.2) | 7 (9.9) | |
T3 | 49 (62.0) | 47 (66.2) | |
T4 | 8 (10.1) | 7 (9.9) | |
Tx | 8 (10.1) | 5 (7.0) | |
Metastatic stage | 0.746* | ||
M0 | 45 (57.0) | 39 (54.9) | |
M1 | 24 (30.4) | 26 (36.6) | |
Mx | 10 (12.6) | 6 (8.5) | |
Gleason score | 0.767* | ||
≤6 | 16 (20.3) | 12 (16.9) | |
7 | 25 (31.6) | 28 (39.4) | |
8 | 13 (16.5) | 12 (16.9) | |
9 | 10 (12.7) | 7 (9.9) | |
10 | 2 (2.5) | 0 (0) | |
Missing | 13 (16.5) | 12 (16.9) | |
Primary treatment | 0.010* | ||
Radical prostatectomy | 6 (7.6) | 3 (4.2) | |
Radiotherapy treatment | 12 (15.2) | 27 (38.0) | |
None | 49 (62.0) | 36 (50.7) | |
Missing | 12 (15.2) | 5 (7.0) | |